Among the freshly rising rosacea treatments, botulinum toxin has captivated focus for its prospective efficacy in furnishing around 4 months of symptomatic reduction. On August 2, 2010, the US FDA announced the approval of incobotulinumtoxinA (Xeomin®) to the treatment of adults with cervical dystonia, to reduce the severity of https://jetonlinepharma.us/product-category/botulinum-toxins/